SeaStar Medical Holding Corporation (ICU)
NASDAQ: ICU · Real-Time Price · USD
0.4051
-0.0148 (-3.52%)
At close: Jun 27, 2025, 4:00 PM
0.4100
+0.0049 (1.21%)
After-hours: Jun 27, 2025, 7:59 PM EDT
SeaStar Medical Holding Employees
SeaStar Medical Holding had 19 employees as of December 31, 2024. The number of employees increased by 7 or 58.33% compared to the previous year.
Employees
19
Change (1Y)
7
Growth (1Y)
58.33%
Revenue / Employee
$22,526
Profits / Employee
-$837,105
Market Cap
4.28M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 19 | 7 | 58.33% |
| Dec 31, 2023 | 12 | 3 | 33.33% |
| Dec 31, 2022 | 9 | 6 | 200.00% |
| Dec 31, 2021 | 3 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ICU News
- 3 days ago - SeaStar Medical Reports Update on Nasdaq Listing Status - GlobeNewsWire
- 4 days ago - SeaStar Medical Announces Two Feature Stories on QUELIMMUNE Adoption and Patient Testimonial of Life-Saving Therapy - GlobeNewsWire
- 8 days ago - SeaStar Medical Announces Pricing of Up to $8 Million Public Offering - GlobeNewsWire
- 17 days ago - AREVA Institute and SeaStar Medical Announce DoD Award of Prestigious Military Grant to AREVA Institute to Evaluate SeaStar Medical's SCD Therapy to Advance Breakthrough Burn and Sepsis Research - GlobeNewsWire
- 4 weeks ago - SeaStar Medical Announces CMS Coverage for Medicare and Medicaid Eligible Patients with Cardiorenal Syndrome Awaiting LVAD in Investigational Trial of SCD Therapy - GlobeNewsWire
- 6 weeks ago - SeaStar Medical Holding Corporation (ICU) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - SeaStar Medical Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 6 weeks ago - SeaStar Medical Reaches Interim Enrollment Target for NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury - GlobeNewsWire